# Cogene Ventures

> Cogene Ventures is a VC fund in Houston backing Biotechnology, Health Care and Medical. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Houston, United States
- Total investments: 6
- Last investment: Mar 2006
- Lead investor: 0%
- Last updated: Aug 2026

Cogene Ventures is a VC fund in Houston focused on Biotechnology and Health Care. Cogene Ventures, a Texas-based venture capital firm, specializes in early-, mid-, expansion-, and late-stage investments.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 100% |
| Health Care | 4 | 67% |
| Medical | 3 | 50% |
| Therapeutics | 3 | 50% |
| Pharmaceutical | 2 | 33% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 2 | 33% |
| Funding Round | 2 | 33% |
| Series B | 1 | 17% |
| Series C | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 83% |
| Canada | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Neuromed Pharmaceuticals | Neuromed Pharmaceuticals is focused on the development, production, and marketing of pain therapies in Canada and the United States. Neuromed Pharmaceuticals was acquired by Zalicus in December 2009. Neuromed Pharmaceuticals was founded in 1998 and is based in Vancouver, Canada. | $25M | Series D | Mar 08, 2006 |  |
| Raven Biotechnologies | Raven biotechnologies, Inc., a biotechnology company, focuses on the development of monoclonal antibody therapeutics for treating cancer. Its lead product candidate, RAV12, targets adenocarcinomas and used for the treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 andis based in South San Francisco, California. As of July 17, 2008, Raven Biotechnologies, Inc. operates as a subsidiary of MacroGenics, Inc. | $48.3M | Series D | Oct 24, 2005 |  |
| Rejuvenon | Rejuvenon a biopharmaceutical company committed developing and commercializing promising compounds for treatment of oncologic diseases. | $37M | Series B | Jun 23, 2004 |  |
| TransMolecular | TransMolecular, Inc. is a neuroscience biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system having inadequate pharmaceutical alternatives. The Company focuses its drug development on cancer and pain, and has built strong technologyplatforms to enrich its product discovery and development pipeline.Founded in July 1996, TransMolecular is privately held and venture capital backed, having raised $9.6MM to date through two private placements from internationally recognized investment firms.The Company has built a strong management team that is dedicated to the discovery and development of safe and effective products for patients suffering from cancer and pain. Its management team has more than 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance. TransMolecular's corporate offices and R&D laboratories are in Birmingham, Alabama.TransMolecular has received three Small Business Incentive Research (SBIR) grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The Company holds more than 25 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively. | $33.2M | Series C | Mar 01, 2004 |  |
| Gyre Therapeutics | Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for thetreatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Founded in 1997, the company is headquartered in South San Francisco, California. | $60M |  | Mar 20, 2003 |  |
| MacroGenics | MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases.The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company'sFc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology.The company was founded in 2000 and is headquartered in Rockville, Maryland. | $12.6M |  | Jun 07, 2002 |  |

6 of 6 investments shown.

## Co-investors
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 2 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 2 deals together
- [Alexandria Real Estate Equities](https://shizune.co/investors/profile/alexandria-real-estate-equities) — VC Fund, 1 deal together
- [Aperture Venture Partners](https://shizune.co/investors/profile/aperture-venture-partners) — VC Fund, 1 deal together
- BCM Technologies (BCMT) — VC Fund, 1 deal together
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Cogene Ventures invest in?

Cogene Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series D and Funding Round stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Cogene Ventures last invest?

The most recent investment recorded for Cogene Ventures closed in Mar 2006. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co